144 related articles for article (PubMed ID: 334328)
1. Blood replacement therapy.
Urbaniak SJ; Cash JD
Br Med Bull; 1977 Sep; 33(3):273-82. PubMed ID: 334328
[No Abstract] [Full Text] [Related]
2. [Substitution therapy of hemorrhagic diseases].
Haupt H
Anasthesiol Intensivmed Prax; 1975 Oct; 11(1):137-44. PubMed ID: 1225069
[No Abstract] [Full Text] [Related]
3. Clotting factor concentrates.
Entwistle CC
Int Anesthesiol Clin; 1985; 23(2):49-59. PubMed ID: 3924836
[No Abstract] [Full Text] [Related]
4. Blood and blood components in the prevention and control of bleeding.
Schmidt PJ; Grindon AJ
JAMA; 1967 Dec; 202(10):967-9. PubMed ID: 5630741
[No Abstract] [Full Text] [Related]
5. [Indications and transfusion of coagulation-active blood fractions].
Mueller-Eckhardt C; Heinrich D; Lasch HG
Z Prakt Anasth; 1970 Dec; 5(6):401-18. PubMed ID: 4256253
[No Abstract] [Full Text] [Related]
6. Effect of plasma and platelet concentrate infusions on factor VIII, platelet adhesiveness, and bleeding time in bleeder swine.
Cornell CN; Cooper RG; Muhrer ME; Garb S
Thromb Diath Haemorrh; 1972 Dec; 28(3):431-9. PubMed ID: 4649277
[No Abstract] [Full Text] [Related]
7. ABC of transfusion. Plasma, plasma products, and indications for their use.
Cohen H; Kernoff PB
BMJ; 1990 Mar; 300(6727):803-6. PubMed ID: 2108781
[No Abstract] [Full Text] [Related]
8. [Blood derivatives in the treatment of hemophilia in Spain. Present and future needs].
Medarde A; Ayesa C; Alfonso L; Muñóz A
Sangre (Barc); 1979; 24(5-C):942-6. PubMed ID: 121170
[No Abstract] [Full Text] [Related]
9. Production of recombinant coagulation proteins.
Vehar GA
Ann N Y Acad Sci; 1987; 509():82-8. PubMed ID: 3122622
[No Abstract] [Full Text] [Related]
10. Cryoprecipitate shortens the bleeding time and reduces bleeding complications in patients with uremia.
Jubelirer SJ; Janson PA; Weinstein MJ; Deykin D
Trans Assoc Am Physicians; 1980; 93():182-91. PubMed ID: 6787774
[No Abstract] [Full Text] [Related]
11. [Problems posed by hemophilia].
Biermé R
Anesth Analg (Paris); 1968; 25(2):125-31. PubMed ID: 5674775
[No Abstract] [Full Text] [Related]
12. [Diagnosis and therapy of various form of thrombopathy].
de Vries SI
Ned Tijdschr Geneeskd; 1970 Jan; 114(4):154-64. PubMed ID: 4905905
[No Abstract] [Full Text] [Related]
13. Selected topics in blood component therapy.
Wallas CH
Prog Clin Pathol; 1984; 9():47-64. PubMed ID: 6420839
[No Abstract] [Full Text] [Related]
14. Blood transfusion: merits of component therapy. II. The clinical use of plasma and plasma components.
Buchholz DH
J Pediatr; 1974 Feb; 84(2):165-72. PubMed ID: 4589841
[No Abstract] [Full Text] [Related]
15. [Principles of modern therapy for hemophilia A and B in childhood].
Ströder J; Ambs E
Dtsch Med Wochenschr; 1968 Mar; 93(12):539-41. PubMed ID: 5639667
[No Abstract] [Full Text] [Related]
16. Hemophilia management in transfusion medicine.
Poon MC; Card R
Transfus Apher Sci; 2012 Jun; 46(3):299-307. PubMed ID: 22503305
[TBL] [Abstract][Full Text] [Related]
17. [Study of the "in vivo" activity of factor VIII or factor IX after injection of several concentrates: practical applications].
Allain JP
Nouv Rev Fr Hematol; 1972; 12(2):241-9. PubMed ID: 4264617
[No Abstract] [Full Text] [Related]
18. Treatment of factor VIII inhibitors.
Kasper CK
Prog Hemost Thromb; 1989; 9():57-86. PubMed ID: 2492380
[No Abstract] [Full Text] [Related]
19. Effects of stroma-free haemoglobin solution on the blood-clotting system in dogs.
Uszyński L; Schier J; Rudowski W; Daszyński J
Eur Surg Res; 1976; 8(3):204-10. PubMed ID: 947758
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of thrombocyte substitutes].
Schneider W
Bibl Haematol; 1971; 37():400-9. PubMed ID: 5003439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
